Insmed Stock Soars on Breakthrough Lung Disease Drug Results
Originally Published 1 year ago — by Yahoo Finance

Insmed Incorporated's stock surged by up to 110% following positive study results for a drug treating bronchiectasis, a chronic lung condition. Analysts are optimistic about the company's future, with plans to file for U.S. market clearance and potential applications for other diseases.